Exelixis, Inc.
EXEL
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.8B
$59.01
▼ -0.20%
P/E
18.21
Mkt Cap
$14.8B
52-Wk Range
$33.76–$59.72
52-Week Range
$33.76 - $59.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced molecular targeting technologies
- Diverse oncology research pipeline
- Strategic pharmaceutical collaborations
- Proven track record of drug development
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Expanding oncology treatment market
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Strong
+14.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying EXEL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 5, 2026
Reported EPS of $0.91 vs $0.85 consensus (+6.7% surprise). Revenue of $628.7M vs $636.4M expected (-1.2%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.7%
Revenue trend · last 8Q
—
+18%
+31%
-11%
+11%
+6%
+10%
+11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
Q2 26
$539.5M
$566.8M
$555.4M
$568.3M
$597.8M
$598.7M
$610.8M
$628.7M
Margins · last 8Q
Gross
0.0%
Operating
39.5%
Profit
33.7%
Wall Street consensus
8 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jul 7, 2026
vs Industry
How EXEL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related